11 results about "Platelet Numbers" patented technology

The invention discloses a hematology analyzer and a platelet numerical value measuring method, in the hematology analyzer, an analysis unit is used for receiving a pulse signal to generate a first image, receiving an optical signal to generate a second image, obtaining a platelet original numerical value based on the first image, obtaining an interference coefficient of a leukocyte fragment based on the second image, and obtaining the platelet numerical value based on the interference coefficient; and obtaining a platelet measurement value based on the platelet original value and the interference coefficient. Through the cooperation of the impedance module and the flow fluorescence module, the platelet original value in the blood cell sample and the interference coefficient of the leukocyte fragment are detected, and the accuracy of each step in the calculation process of the platelet measurement value is ensured. Meanwhile, the platelet measurement numerical value is calculated through the analysis unit based on the platelet original numerical value and the interference coefficient, so that the accuracy of the blood cell analyzer for measuring the platelet measurement numerical value is improved, the practicability of the blood cell analyzer is improved, and the use experience of a user on the blood cell analyzer is improved.

This invention discloses the application and method of a STAT1-targeting inhibitor in the treatment of immune thrombocytopenic purpura (ITP). It employs ivermectin, a STAT1 nuclear translocation inhibitor, and fludarabine, a STAT1 activation inhibitor. By injecting either the activation inhibitor or the nuclear translocation inhibitor, the platelet count in a mouse model of ITP is increased. Fludarabine, a fluorinated nucleotide analog of vidarabine, is non-radioactive and a small-molecule phosphorylation inhibitor. Ivermectin is a small-molecule inhibitor of nuclear translocation mediated by α / β1 introgression protein. Both have high bioavailability and are widely used to treat various hematological diseases with good safety profiles. Their application in treating ITP is safe, effective, and shows high compliance.

GABRR1 is shown to be expressed on subsets of hematopoietic stem cells (HSCs) and megakaryocyte progenitors (MkPs). Inhibition of GABRR1 inhibits MkP differentiation and reduction of platelet numbers in blood. Overexpression of GABRR1 or treatment with agonists significantly promotes MkP generation and growth of megakaryocytes.

This invention relates to the field of platelet aggregation function detection technology, specifically to a composition, apparatus, and detection method for determining platelet count. The composition provided by this invention for determining platelet count includes the following components: a platelet activator and optical particles, wherein the optical particles are coated with a bioactive material that binds to platelet surface receptors. This invention employs a combination of a platelet activator and optical particles coated with bioactive material that binds to platelet surface receptors. In the presence of a blood sample, platelets activated by the platelet activator aggregate with the optical particles, causing a change in the light signal, thereby enabling the determination of changes in platelet count.

This invention relates to the field of biomedical detection technology, specifically a method for detecting platelet-rich plasma based on biosensors. The method includes: preparing a biosensor interface capable of recognizing platelet surface-specific antigens; applying the sample to be tested to the interface for a specific binding reaction; monitoring signal changes during the reaction process in real time and acquiring raw data; preprocessing the data to obtain a purification response curve; extracting characteristic parameters such as binding rate, equilibrium response value, and dissociation rate constant from the curve; and finally, analyzing the above parameters based on a pre-established quantitative relationship model to simultaneously calculate the platelet concentration and platelet activation index of the sample. This method achieves simultaneous, rapid, and integrated quantitative assessment of platelet quantity and functional activity in platelet-rich plasma.

This invention relates to the use of hydroxysaffron yellow A in the treatment of platelet-related diseases. Specifically, this invention provides a use of hydroxysaffron yellow A for preparing compositions for the prevention and / or treatment of platelet-related diseases. This invention discovers that hydroxysaffron yellow A can reduce platelet count and the ratio of large platelets, as well as inhibit platelet aggregation and agglutination, for the prevention and treatment of diseases associated with elevated platelet counts such as thrombocytosis, diseases associated with elevated large platelet ratios, and diseases associated with platelet activation, thereby preventing and treating platelet-related diseases.

The invention relates to the technical field of biomedicine detection, in particular to a platelet-rich plasma detection method based on a biosensor, which comprises the following steps: preparing a biosensing interface with a recognition function on platelet surface specific antigens; a sample to be detected is applied to the interface for a specific binding reaction; monitoring signal change in the reaction process in real time and acquiring original data; preprocessing the data to obtain a purification response curve; extracting characteristic parameters such as a binding rate, a balance response value and a dissociation rate constant; and finally, based on a pre-established quantitative relation model, analyzing the parameters, and synchronously calculating the platelet concentration value and the platelet activation index of the sample. According to the method, synchronous, rapid and integrated quantitative evaluation on the quantity and functional activity of platelets in the platelet-rich plasma is realized.

The application discloses a Lactobacillus rhamnosus GG ferment with the function of promoting the immunity of patients and a preparation method thereof. The ferment is obtained by fermenting a composition by Lactobacillus rhamnosus GG, and the composition comprises the following components in parts by weight: 8-15 parts of full-fat milk powder, 1-4 parts of concentrated milk protein, 2-7 parts of soybean milk powder, 3-13 parts of glucose, 1-4 parts of fructose glucose syrup, 0.2-0.6 parts of yeast beta-glucan and 60-80 parts of water. The Lactobacillus rhamnosus GG ferment with the function of promoting the immunity of patients contains a high concentration of active Lactobacillus rhamnosus GG in particular. After patients who are taking medicine eat the ferment, the number of platelets in the blood of the patients can be significantly increased, so that the immunity of the patients is improved and the recovery of the patients is promoted.

This application provides a molecular marker in the bovine CSAD gene and its application. The molecular marker is one or more of g.26839616 T>C and g.26842339 C>T in the bovine genome. The molecular marker provided in this application, or the substance used to detect single nucleotide polymorphisms in bovine molecular markers, can be used in bovine genetic breeding to increase platelet count in Tibetan improved cattle offspring and solve the hypoxia bottleneck problem faced in the breeding of plateau cattle.

The application provides a molecular marker related to sheep immunity traits and application thereof. The application uses a method for detecting a PLEKHH2 gene SNP site of Lake sheep by combining DNA pool sequencing with KASPar technology. A primer is designed according to a PLEKHH2 gene sequence, DNA is extracted from sheep blood, and PCR amplification, DNA sequencing and sequence analysis are carried out, so that a C / G polymorphic site at the 368th position of the amplified fragment is found. Further, KASPar primers are used to detect the polymorphic site of 889 Lake sheep and to establish a least square model, and correlation analysis is carried out on the genotype and immunity trait indexes, so that it is found that the site is significantly related to the platelet count (PLT) and the mean corpuscular hemoglobin concentration (MCHC) of sheep. Through detection of the molecular marker of the application, the application can be used in marker-assisted disease-resistant breeding of sheep and can accelerate the breeding process of sheep.

The invention discloses a CD36 antigen deletion type typing detection plate, a detection method and a detection kit. According to the detection plate provided by the invention, the CD36 antigens of blood platelets and mononuclear cells can be simultaneously detected in the same plate, and the deletion type of the CD36 antigens can be intuitively judged according to the detection result, so that repeated detection is not needed, the overall detection time is shortened, and the detection result can be quickly obtained. Sample pretreatment is not needed, and the requirements for equipment and technicians are low. The detection specificity is good, the accuracy is high, and the reliability is strong. The detection plate provided by the invention can realize large-flux and full-automatic detection, is suitable for batch screening of platelet CD36 deficiency and high-flux detection of a blood sample, defines CD36 antigen expression data of the blood sample or the platelet sample, provides great convenience and feasibility for establishment of a platelet database, and has a wide application prospect. The formation of a platelet database is promoted, and the method has extremely important significance on blood transfusion safety.